Digoxin API supply secured through acquisition

By Maggie Lynch

- Last updated on GMT

(Image: Getty/rawpixel)
(Image: Getty/rawpixel)

Related tags API acquistion Supply chain India

C2 Pharma acquires digoxin API product portfolio from Noblius to secure supply of the ingredient, after disruption of the supply of the API for a number of years.

C2 Pharma, a Luxembourg-based phytochemical and chemical-pharmaceutical company, secured its supply of the active pharmaceutical ingredient (API) digoxin, through the acquisition of Nobilus’ API product portfolio.

The availability of digoxin API has been disrupted since 2014. Marcelo Reinhardt, senior director of business development at C2 Pharma, told us the disruption has been “due to the inability of the manufacturers and their digitalis leaf growers to supply the marketplace reliably.”

Per the acquisition, a full supply of the API will be available from C2 Pharma through two sources of manufacturing with its partners Nobilus in Poland and Laurus Labs in India.

To mitigate the risk of unreliable product posed with the manufacture of digoxin, C2 Pharma will set up a fully independent supply chain and continue to invest in a dedicated manufacturing facility for Laurus Labs.

The company invested around $10m (€8.84m) in the fully dedicated production facility at Laurus site in Vizag, India.  According to Reinhardt, the plant is 1,800m2 ​and has an annual production output which covers the global demand for digoxin.

This agreement sees C2 Pharma become the owner of the API product portfolio and Nobilus become its manufacturing and distribution group. Reinhardt explained that while Digoxin does not have a large market, it is a niche but global API and is classified as an essential drug by the World Health Organization. 

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...